Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P.V. Carroll, E.R. Christ, B.A. Bengtsson, L. Carlsson, J.S. Christiansen, D. Clemmons, et al.
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee.
J Clin Endocrinol Metab, 83 (1998), pp. 382-395
[2.]
H. De Boer, G.J. Block, E. Van der Veen.
Clinical aspects of growth hormone deficiency in adults.
Endocrine Reviews, 16 (1995), pp. 63-86
[3.]
A.S. Bates, W. Van’t Hoff, P.J. Jones, R.N. Clayton.
The effect of hypopituitarism on life expectancy.
J Clin Endocrinol Metab, 81 (1996), pp. 1169-1172
[4.]
M.L.M.N. Vance.
Growth hormone therapy in adults and children.
N Eng J Med, 341 (1999), pp. 1206-1216
[5.]
Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab. 1998;83:379-81.
[6.]
R.C. Cuneo, F. Salomon, G.A. MacGauley, P.H. Sönksen.
The growth hormone deficiency syndrome in adults.
Clin Endocrinol( Oxf), 37 (1992), pp. 387-397
[7.]
H.B.A. Baum, B.M.K. Biller, J.S. Finkelstein, K.B. Cannistraro, D.S. Oppenheim, D.A. Schenfeld, et al.
Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency: a randomized, placebo-controlled trial.
Ann Intern Med, 125 (1996), pp. 883-890
[8.]
S.A. Beshyah, C. Freemantle, E. Thomas, O. Rutherford, B. Page, M. Murphy, et al.
Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults.
Clinical Endocrinology (Oxf), 42 (1995), pp. 179-189
[9.]
A. Binnerts, P. Deurenberg, G.R. Swart, J.H. Wilson, S.W. Lambert.
Body composition in growth hormone-deficient adults.
Am J Clin Nutr, 55 (1992), pp. 918-923
[10.]
R.C. Cuneo, F. Salomon, C.M. Wiles, P.H. Sönksen.
Skeletal muscle performance in adults with growth hormone deficiency.
Horm Res, 35 (1990), pp. 55-60
[11.]
H. De Boer, G.J. Blok, H.J. Voerman, M. Phillips, J.A. Schouten.
Serum lipid levels in growth hormone deficient men.
Metabolism, 43 (1994), pp. 199-203
[12.]
T. Rosen, L. Wirén, L. Wilhelmsen, I. Wiklund, B.A. Bengtsson.
Decreased psychological well-being in adult patients with hormone deficiency.
Clin Endocrinol (Oxf), 40 (1994), pp. 111-116
[13.]
G. Amato, C. Carella, S. Fazio, G. La Montagna, A. Cittadini, D. Sabatini, et al.
Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses.
J Clin Endocrinol Metab, 77 (1993), pp. 1671-1676
[14.]
S.A. Beshyah, C. Freemantle, M. Shabi, V. Anyaoku, S. Merson, S.E. Lynch, et al.
Replacement treatment with biosynthetic growth hormone in growth hormone-deficient hypopituitary adults.
Clin Endocrinol (Oxf), 42 (1995), pp. 73-84
[15.]
R.C. Cuneo, F. Salomon, G.F. Watts, R. Hesp, P.H. Sönksen.
Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency.
Metabolism, 42 (1993), pp. 1519-1523
[16.]
H.B. Baum, B.M. Biller, L. Katznelson, D.S. Oppenheim, D.R. Clemmons, K.B. Cannistraro, et al.
Assessment of growth hormone (GH) secretion in men with adult onset deficiency compared with that in normal men-a clinical research center.
J Clin Endocrinol Metab, 81 (1996), pp. 84-92
[17.]
H.B. Baum, L. Katznelson, J.C. Sherman, B.M. Biller, D.L. Hayden, D.A. Schoenfeld, et al.
Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency.
J Clin Endocrinol Metab, 83 (1998), pp. 3184-3189
[18.]
H.B. Baum, B.M. Biller, J.S. Finkelstein, K.B. Cannistraro, D.S. Oppenhein, D.A. Schoenfeld, et al.
Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency: a randomized, placebo-controlled trial.
Ann Intern Med, 125 (1996), pp. 883-890
[19.]
G. Johansson, T. Rosen, I. Bosaeus, L. Sjostrom, B.A. Bengtsson.
Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult onset GH deficiency.
J Clin Endocrinol Metab, 81 (1996), pp. 2865-2867
[20.]
R.C. Cuneo, S. Judd, J.D. Wallace, et al.
The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
J Clin Endocrinol Metab, 83 (1998), pp. 107-116
[21.]
A. Colao, P. Marzullo, C. Di Somma, G. Lombardi.
Growth hormone and the heart.
Clin Endocrinol (Oxf), 54 (2001), pp. 137-154
[22.]
J. Gibney, J.D. Wallace, T. Spinks, L. Schnorr, A. Ranicar, R.C. Cuneo, et al.
The effect of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients.
J Clin Endocrinol Metab, 84 (1999), pp. 2596-2602
[23.]
A. Chrisoulidou, S.A. Beshyah, O. Rutherford, T.J. Spinks, J. Mayet, F. Kyd, et al.
Effects of 7 years of growth hormone replacement therapy in hypopituitary adults.
J Clin Endocrinol Metab, 85 (2000), pp. 3762-3769
[24.]
J. Verhelst, R. Abs, M. Vandeweghe, J. Mockel, J.J. Legros, G. Copinschi, et al.
Two years of replacement therapy in adults with growth hormone deficiency.
Clin Endocrinol (Oxf), 47 (1997), pp. 485-494
[25.]
J.J. Díez.
El síndrome de deficiencia de hormona de crecimiento en adultos: criterios actuales para el diagnóstico y tratamiento.
Med Clin (Barc), 114 (2000), pp. 468-477
[26.]
S.M. Shalet, A. Toogood, A. Rahim, B.M. Brennan.
The diagnosis of growth hormone deficiency in children and adults.
Endocr Rev, 19 (1998), pp. 203-223
[27.]
L.A. Frohman.
Controversy about treatment of growth hormonedeficient adults: a commentary.
Ann Intern Med, 137 (2002), pp. 202-204
[28.]
R.D. Murray, C.J. Skillicorn, S.J. Howell, C.A. Lissett, A. Rahim, S.M. Shalet.
Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults.
Clin Endocrinology (Oxf), 50 (1999), pp. 749-757
[29.]
A.A. Toogood, S.M. Shalet.
Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study.
J Clin Endocrinol Metab, 84 (1999), pp. 131-136
[30.]
B.A. Bengtsson, R. Abs, H. Bennmarker, J.P. Monson, U. Feldt- Rasmussen, E. Hernberg-Stahl, et al.
The effects of treatment and the individual responsiveness to growth hormone (GH) replacement in 665 GH-deficient adults. KIMS Study Group International board.
J Clin Endocrinol Metab, 84 (1999), pp. 3929-3935
[31.]
D.M. Cook, W.H. Ludlan, M.B. Cook.
Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH Deficient adults.
J Clin Endocrinol Metab, 84 (1999), pp. 3956-3960
[32.]
W.M. Drake, S.J. Howell, J.P. Monson, S.M. Shalet.
Optimizing GH therapy in adults and children.
Endocrine Rev, 22 (2001), pp. 425-450
[33.]
P. Burman, A.G. Johansson, A. Siegbahn, B. Vessby, F. Karlsson.
Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women.
J Clin Endocrinol Metab, 82 (1997), pp. 550-555
[34.]
Y.JH. Janssen, F. Helmerhorst, M. Frolich, F. Roelfsema.
A switch from oral (2 mg/day) to transdermal (50 μg/day) 17-β- estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency.
J Clin Endocrinol Metab, 85 (2000), pp. 464-467
[35.]
J.P.T. Span, G.F.F.M. Pieters, C.G.J. Sweep, A.R.M.M. Hermus, A.G.H. Smals.
Gender difference in insulin-like growth factor-I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement.
J Clin Endocrinol Metab, 85 (2000), pp. 1121-1125
[36.]
H. De Boer, G.J. Blok, C. Popp-Snijders, L. Stuurman, R.C. Baxter, E. Van der Veen, et al.
Monitoring of growth hormone replacement therapy in adults based on measurements of serum markers.
J Clin Endocrinol Metab, 81 (1996), pp. 1371-1377
[37.]
C.B. Newman, D.L. Kleinberg.
Adult growth hormone deficiency.
Endocrinologist, 8 (1998), pp. 178-186
[38.]
S. Blethen.
Dosing, monitoring, and safety of growth hormonereplacement therapy in adults with growth hormone deficiency.
Endocrinologist, 8 (1998), pp. S36-40
[39.]
J.M. Chan, M.J. Stampfer, J. Ma, P. Gann, J.M. Gaziano, M. Pollack, et al.
Insulin-like growth factor-I (IGF-1) and IGF binding protein-3 as predictors of advance-stage prostate cancer.
J Natl Cancer Inst, 94 (2002), pp. 1099-1106
[40.]
S.E. Hankinson, W.C. Willett, G.A. Colditz, D.J. Hunter, D.S. Michaud, B. Deroo, et al.
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.
Lancet, 351 (1998), pp. 1393-1396
[41.]
H. Yu, T. Rohan.
Role of the insulin-like growth factor family in cancer development and progression.
J Natl Cancer Inst, 92 (2000), pp. 1472-1489
[42.]
S. Orme, R.J.Q. McNally, R.A. Cartwright, P.E. Belchetz.
Mortality and cancer incidence in acromegaly: a retrospective cohort study.
J Clin Endocrinol Metab, 83 (1998), pp. 2730-2734
[43.]
C. Sklar.
Paying the price for cure: treating cancer survivors with growth hormone.
J Clin Endocrinol Metab, 85 (2000), pp. 4441-4443
[44.]
A.J. Swerdlow, R.E. Reddingius, C.D. Higgins, H.A. Spoudeas, K. Phipps, Z. Qiao, et al.
Growth hormone treatment of children with brain tumors and risk of tumor recurrence.
J Clin Endocrinol Metab, 85 (2000), pp. 4444-4449
[45.]
J.P. Monson.
Long-term experience with GH replacement therapy: efficacy and safety.
Eur J Endocrinol, 148 (2003), pp. S9-14
[46.]
B.A. Bengtsson, H.P. Koppeschaar, R. Abs, H. Bennmarker, E. Hemberg-Stahl, B. Westbert, et al.
Growth hormone replacement therapy is not associated with any increase in mortality. KIMS Study Group.
J Clin Endocrinol Metab, 84 (1999), pp. 4291-4292
[47.]
A.F. Attanasio, S.W. Lamberts, A.M. Matranga, M.A. Brukett, P.G. Bates, M.K. Valk, et al.
Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Growth Hormone Deficiency Study Group.
J Clin Endocrinol Metab, 82 (1997), pp. 82-88
[48.]
J. Koranyi, J. Svensson, G. Göterström, K.S. Sunnerhagen, B. Bengtsson, G. Johanaaon.
Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood and adulthood onset: a comparative prospective study.
J Clin Endocrinol Metabol, 86 (2001), pp. 4693-4699
[49.]
P. Burman, A.G. Johansson, A. Siegebahn, B. Vessby, F.A. Karlsson.
Growth hormone (GH)-deficient men are more responsive to GH replace therapy that women.
J Clin Endocrinol Metab, 82 (1997), pp. 550-555
[50.]
G. Saggese, G.I. Baroncelli, S. Bertelloni, S. Barsanti.
The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass.
J Clin Endocrinol Metab, 81 (1996), pp. 3077-3083
[51.]
H. De Boer, E. Van der Veen.
Why retest young adults with childhood-onset growth hormone deficiency?.
J Clin Endocrinol Metab, 82 (1997), pp. 2032-2036
En nombre del grupo de trabajo de neuroendocrinología de la sociedad española de endocrinología y nutrición.
Copyright © 2005. Sociedad Española de Endocrinología y Nutrición
